AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Swiss biopharma AC Immune has released positive updates this week on both its Alzheimer's and Parkinson's disease treatments. Investors are piling in to ACIU stock.

ACIU Stock: Why AC Immune Shares Are Rocketing Higher Today

Biotech company AC Immune said Thursday its Alzheimer's vaccine generated key antibodies in the brain, leading ACIU stock to pop. Shares hit a three-year high in premarket action.

Alzheimer's Vaccine Prods AC Immune Stock To A Seven-Month High

AC Immune SA (NASDAQ: ACIU) soars in premarket on robust volume, on the heels of positive interim results from its ongoing Phase 1b/2a trial evaluating its anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease. ACI-35.030 is under development in collaboration with Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals under a 2014 agreement.

AC Immune's Alzheimer's Vaccine Candidate Elicit Response In Early-Stage Study; Shares Rally

The stock price of AC Immune SA (NASDAQ: ACIU) is trading at over 130% pre-market. This is why it happened.

ACIU Stock Price Increases Over 130% Pre-Market: Why It Happened

Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer's disease

AC Immune's Alzheimer's Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that the first patient has been scanned in a first-in-human study of its novel diagnostic agent for Parkinson's disease (PD). ACI-12589 is a next-generation positron emission tomography (PET) imaging tracer that has shown significant potential to reliably detect and map deposits of pathological alpha-synuclein protein in the brain, which is the major hallmark of PD. AC Immune expects to report the results of the study in Q3 2021. The clinical study is supported by the Michael J. Fox Foundation for Parkinson's Research (MJFF), building on The Foundation's significant funding of AC Immune's program since 2015.

AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson's Disease

Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors

AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway

Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital

AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

Prof. June is a world authority on immune tolerance and adoptive immunotherapy

Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune's Board of Directors

Prof. Streffer is a n established authority on n euroscience and b iomarker modalities

Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer

Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat the estimate of ($0.28).

AC Immune: Q3 Earnings Insights

LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for Q3 2020 and provided a business update. The Company ended the third quarter with CHF 246.6 million in cash, which ensures operations are fully financed through Q1 2024 allowing the Company to advance our clinical and preclinical projects to key value inflection points while investing further in our diverse pipeline.

AC Immune Reports Q3 2020 Financial Results and Provides Business Update

Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune's Anti-TDP-43 Antibodies into Clinical Development

AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer.

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Grant from the ‘ EU Joint Programme – Neurodegenerative Disease Research ’ (JPND) provides €1.45M in funding for the program

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.

AC Immune's Candidate Fails in Alzheimer's Disease Study

AC Immune S.A. (NASDAQ: ACIU) stock was absolutely crushed on Wednesday after one of the firm’s partners announced disappointing results from its midstage Alzheimer’s disease study.

Is It Over for AC Immune After This Alzheimer’s Study?

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) have lost about half their market capitalization on an adverse clinical readout for an out-licensed investigational Alzheimer's drug.

Why Shares Of Small-Cap Biopharma AC Immune Are Plunging

AC Immune's experimental Alzheimer's-disease drug missed the mark in a midstage trial.

Why AC Immune Stock Is Crashing Today

Genentech disclosed that the anti-Tau antibody  did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study ; the primary safety endpoint was met

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

LAUSANNE, Switzerland, Sept.  11, 2020  (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase recent progress in its clinical programs targeting Tau for neurodegenerative diseases at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference.

AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference

Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.

Do Options Traders Know Something About AC Immune (ACIU) Stock We Don't?

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy

AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates

First-in-class TDP-43 antibody developed using SurpraAntigen™ platform

News for AC Immune Stock (ACIU)